Circulating ICAM-1 and VCAM-1 Levels in Patients with Obstructive Sleep Apnea SyndromeUrsavaş A.a · Karadağ M.a · Rodoplu E.a · Yılmaztepe A.b · Oral H.B.c · Gözü R.O.a
Departments of aPulmonary Medicine and Tuberculosis, bBiochemistry, and cMicrobiology and Infectious Diseases, Immunology Unit, Medical Faculty, Uludag University, Bursa, Turkey
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Obstructive sleep apnea syndrome (OSAS)-induced hypoxic stress modulates circulating inflammatory mediators causing accelerated atherogenesis. Objectives: We hypothesized that OSAS-induced hypoxia might result in cardiovascular disease due to increased expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on the endothelial surface. Methods: Thirty-nine subjects with moderate-to-severe OSAS and 34 non-apneic controls matched for age, gender, body mass index (BMI), smoking history, and cardiovascular disease were included in this prospective study. Overnight polysomnography was performed. Circulating ICAM-1 and VCAM-1 levels in the serum were measured by enzyme-linked immunosorbent assay. Results: Circulating levels of both ICAM-1 (480.1 ± 216.7 vs. 303.4 ± 98.6 ng/ml, p < 0.0001) and VCAM-1 (1,156.6 ± 79.8 vs. 878.8 ± 71.1 ng/ml, p = 0.002) were significantly increased in the OSAS group compared to the control group. For an ICAM-1 cutoff level of 375 ng/ml, predictive sensitivity and specificity for OSAS were 69.2% (95% confidence interval, CI: 52.4–83.0%) and 82.4% (95% CI: 65.5–93.2%), respectively. For a VCAM-1 cutoff level of 859 ng/ml, predictive sensitivity and specificity for OSAS were 74.4% (95% CI: 57.9–86.9%) and 64.7% (95% CI: 46.5–80.2%), respectively. There was a significant positive correlation between circulating levels of ICAM-1 and ln of AHI (r = 0.276, p = 0.018). Multiple logistic regression analyses showed that OSAS was associated with high ICAM-1 and high VCAM-1 levels independent of age, gender, BMI, smoking status and cardiovascular disease. Conclusion: We conclude that OSAS can independently increase circulating levels of adhesion molecules.
© 2006 S. Karger AG, Basel
ASDA-Diagnostic Classification Steering Committee. The International Classification of Sleep Disorders. Diagnostic and Coding Manual, ed. 2. Lawrance, Allen, 1997.
Hedner J, Grote L: Cardiovascular consequences of obstructive sleep apnea. Eur Respir Mon 1998;10:227–265.
- Bixler EO, Vgontzas AN, Lin HM, et al: Prevalence of sleep-disordered breathing in women; effects of gender. Am J Respir Crit Care Med 2001;163:608–613.
- Roux F, D’Ambrosio C, Mohsenin V: Sleep-related Breathing disorders and cardiovascular disease. Am J Med 2000;108:396–402.
Nieto FJ, Young TB, Lind BK, et al: Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829–1836.
- Peker Y, Hedner J, Norum J, et al: Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med 2002;166:159–165.
- Andreas S, Schulz R, Werner G, et al: Prevalence of obstructive sleep apnea in patients with coronary artery disease. Coron Artery Dis 1996;7:541–545.
Ross R: Atherosclerosis is an inflammatory disease. Am Heart J 1999;138(5 Pt 2):419–420.
- Libby P: Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 2003;91:3a–6a.
- Wilcox I, McNamara SG, Collins FL, et al: ‘Syndrome Z’: the interaction of sleep apnea, vascular risk factors and heart disease. Thorax 1998;53(suppl 3):S25–S28.
- Amberger A, Maczek C, Jurgens G, et al: Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and human endothelial cells in response to cytokines and oxidized low-density lipoproteins. Cell Stress Chaperones 1997;2:94–103.
- Arnould T, Michiels C, Remacle J: Increased PMN adherence on endothelial cells after hypoxia: involvement of PAF CD18/CD11b and ICAM-1. Am J Physiol 1993;264(5 Pt 1):C1102–C1110.
- Springer TA: Adhesion receptors of the immune system. Nature 1990;346:425–434.
- Li H, Cybulski MI, Gimbrone MA Jr, et al: An atherogenic diet rapidly induces VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993;13:197–204.
Rechtschaffen A, Kales A (eds): A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects, ed 3. Los Angeles, Brain Research Institute, 1973, pp 1–13.
- Hla KM, Young TB, Bidwell T, et al: Sleep apnea and hypertension. A population-based study. Ann Intern Med 1994;120:382–388.
- Fletcher EC, Debehnke RD, Lovoi MS, et al: Undiagnosed sleep apnea in patients with essential hypertension. Ann Intern Med 1985;103:190–195.
- Mooe T, Rabben T, Wiklund U, et al: Sleep-disordered breathing in men with coronary artery disease. Chest 1996;109:659–663.
- Mooe T, Rabben T, Wiklund U, et al: Sleep-disordered breathing in women: occurrence and association with coronary disease. Am J Med 1996;101:251–256.
- Oflaz H, Cuhadaroglu C, Pamukcu B, et al: Endothelial function in patients with obstructive sleep apnea syndrome but without hypertension. Respiration 2006;73:751–756.
- Dıncer HE, O’Neill W: Deleterious effects of sleep disordered breathing on the heart and vascular system. Respiration 2006;73:124–130.
- Hwang SJ, Ballantyne CM, Sharrett AR, et al: Circulating adhesion molecules ICAM-1, VCAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (Aric) Study. Circulation 1997;96:4219–4225.
- Ridker PM, Hennekens CH, Roitman-Johnson B, et al: Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet 1998;351:88–92.
- Rohde LE, Hennekens CH, Ridker PM, et al: Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler Thromb Vasc Biol 1999;19:1595–1599.
- De Caterina R, Basta G, Lazzerini G, et al: Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2646–2654.
- Blankenberg S, Ruppecht HI, Bickel C, et al: Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336–1342.
- van der Meer IM, de Maat MP, Bots ML, et al: Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 2002;22:838–842.
- Blann AD, Lip GY, McCollum CN: Changes in von Willebrand factor and soluble ICAM, but not soluble VCAM, soluble E-selectin or soluble thrombomodulin, reflect the natural history of the progression atherosclerosis. Atherosclerosis 2002;165:389–491.
- Jenny NS, Arnold AM, Kuller LH, et al: Soluble intracellular adhesion molecule-1 is associated with cardiovascular disease risk and mortality in older adults. J Thromb Haemost 2006;4:107–113.
- Alberti A, Sarchielli P, Gallinella E, et al: Plasma cytokine levels in patients with obstructive sleep apnea syndrome: preliminary study. J Sleep Res 2003;12:305–311.
- Ciftci Tu, Kokturk O, Bukan N, Bilgihan A: The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 2004;28:87–91.
- Imagawa S, Yamaguchi Y, Ogawa K, et al: Interleukin-6 and tumor necrosis factor-α in patients with obstructive sleep apnea-hypopnea syndrome. Respiration 2004;71:24–29.
- Hatipoğlu U, Rubinstein I: Inflammation and obstructive sleep apnea syndrome pathogenesis: a working hypothesis. Respiration 2003;70:665–671.
- Price DT, Loscalzo J: Cellular adhesion molecules and atherogenesis. Am J Med 1999;107:85–97.
- Lattimore JD, Wilcox I, Nakhla S, et al: Repetitive hypoxia increases lipid loading in human macrophages – a potentially atherogenic effect. Atherosclerosis 2005;179:255–259.
- Ohga E, Nagase T, Tomita T, et al: Increased levels of circulating ICAM-1, VCAM-1 and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol 1999;87:10–14.
- El-Solh AA, Mador MJ, Sikka P, et al: Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 2002;121:1541–1547.
- Ohga E, Tomita T, Wada H, et al: Effects of obstructive sleep apnea on circulating ICAM-1, IL-8 and MCP-1. J Appl Physiol 2003;94:179–184.
- Koundouros E, Odell E, Coward P, et al: Soluble adhesion molecules in serum of smokers and nonsmokers, with and without periodontitis. J Periodontal Res 1996;31:596– 599.
- Blann Ad, Steele C, Mccollum C: The influence of smoking on soluble adhesion molecules and endothelial cell markers. Thromb Res 1997;85:433–438.
- Demerath E, Towne B, Blangero J, Siervogel RM: The relationship of soluble ICAM-1, VCAM-1, P-selectin and E-selectin to cardiovascular disease risk factors in healthy men and women. Ann Hum Biol 2001;28:664–678.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.